

A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms

Joshua F. Zeidner,¹ Judith E. Karp,¹ Amanda L. Blackford,² B. Douglas Smith,¹ Ivana Gojo,¹ Steven D. Gore,¹ Mark J. Levis,¹ Hetty E. Carraway,¹ Jacqueline M. Greer,¹ S. Percy Ivy,³ Keith W. Pratz,¹ and Michael A. McDevitt^{1,4}

¹Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD; ²Department of Oncology Biostatistics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD; ³National Cancer Institute, Bethesda, MD; and ⁴Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA

©2014 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2013.097246

Manuscript received on August 28, 2013. Manuscript accepted on December 18, 2013.

Correspondence: jzeidner@jhmi.edu / mmcdevi1@jhmi.edu

Supplemental Table 1: Characteristics of Patients (n=37)

Patient	Disease State	Age	% BM blasts at Dx	Splenomegaly at Dx- Radiology and/or Physical Exam	European MF Fibrosis Score- baseline	Cytogenetics at Dx	JAK2 V617F mutation?	Prior Therapies	Response	Splenomegaly Response by Physical Exam	Cytogenetic Response	European MF Fibrosis Score- Best Response
1	Secondary AML (CMML)	72	50%	No	MF-0	46XY	N/A	Arsenic, Azacitidine, Azacitidine + Entinostat, Splenectomy	NR	N/A	N/A	N/A
2	CMML	53	5%	No	MF-3	47XX,+21	N/A	Hydroxyurea	NR	N/A	None	N/A
3	MPN (MF)	60	5%	No	MF-3	CK ¹	N/A	Hydroxyurea, splenectomy	PR	N/A	None	MF-2
4	Secondary AML (MPN)	75	50%	Yes- mild splenomegaly seen on CT, not detected on physical exam	MF-0	46XX	N/A	Hydroxyurea, Tipifarnib + Etoposide	CR	N/A	N/A	MF-0
5	Secondary AML (MPN)	68	80%	No	MF-0	CK/MK ²	N/A	None	NR	N/A	None	N/A
6	MPN (MF)	62	9%	No	MF-3	46XX, del(13)(q12q22)	N/A	Erythropoietin, Thalidomide, Cyclophosphamide	NR	N/A	None	N/A
7	Secondary AML (CMML)	75	20%	Yes- splenomegaly on CT, not detected on physical exam	MF-0	48XX,+8,+11	N/A	Hydroxyurea	CR	N/A	Yes	MF-0
8	Secondary AML (MPN)	60	30%	No	MF-0	CK	N/A	Allogeneic SCT	CR	N/A	None	MF-0
9	Secondary AML (MPN)	72	50%	Yes- splenomegaly on CT, 5 cm below costal margin on physical exam	MF-0	CK/MK	N/A	Hydroxyurea	NE ³	No	N/A	N/A
10	Secondary AML (MPN)	56	80%	Yes- marked splenomegaly on CT, crossed midline and below umbilicus on physical exam	MF-0	CK	N/A	Cyclophosphamide, Hydroxyurea	PR	Yes- 4 cm below costal margin- cycle 3, day 1	None	MF-0
11	Secondary AML (MPN)	63	50%	Yes- splenomegaly on CT, not detected on physical exam	MF-1	46XX,del(20)(q13.1)	N/A	Allogeneic SCT, Azacitidine + Entinostat, Vorinostat, Hydroxyurea	PR	N/A	None	MF-2
12	CMML	62	15%	No	MF-0	46XY	N/A	Erythropoietin	NR	N/A	N/A	N/A
13	Secondary AML (CMML)	50	70%	No	MF-0	46XY	N/A	Splenectomy, Hydroxyurea	PR	N/A	N/A	MF-0

14	Secondary AML (MPN)	67	20%	Yes- splenomegaly on CT, crosses midline in deep pelvis on physical exam	MF-2	CK	N/A	Allogeneic SCT, Splenic radiation	SD ⁴	No	None	MF-2
15	CMML	60	6%	Yes- marked splenomegaly on CT, 5 cm below costal margin on physical exam	MF-0	46XY	N/A	Hydroxyurea	CR	Yes- spleen tip palpable 1-2 cm below costal margin- cycle 3, day 5	N/A	MF-0
16	Secondary AML (MPN)	71	20%	Yes- splenomegaly on CT, not detected on physical exam	MF-2	CK/MK	N/A	Hydroxyurea, Anagrelide, Busulfan	SD	N/A	None	MF-1
17	Secondary AML (CMML)	69	20%	No	MF-0	46XX	Negative	None	CR	N/A	N/A	MF-0
18	CML-BC	64	20%	Yes- splenomegaly on CT, 5-6 cm below costal margin on physical exam	MF-0	46XX,t(9;22)(q34;q11.2),del(12)(p12p13)[15]/50,XX,+7,+8,t(9;22)(q34;q11.2),del(12)(p12p13),+21,+der(22)t(9;22)	Negative	None	NE	No	N/A	N/A
19	Secondary AML (MPN)	68	48%	Yes- mild to moderate splenomegaly on CT, not detected on physical exam	MF-0	47XY,+8	N/A	None	SD	No	None	MF-0
20	CML-BC	57	88%	No	MF-0	46,sl,r(7)(p?22q?36),add(16)(p13.3),-19,+der(22),t(9;22]	Negative	Imatinib, Dasatinib	CR	N/A	Yes	MF-0
21	Secondary AML (CMML)	64	80%	Yes- splenomegaly on CT, not detected on physical exam	MF-0	CK	Negative	Allogeneic SCT, Azacitidine + Entinostat, FLAM, Allogeneic SCT (2 nd), Hydroxyurea	NR	N/A	None	N/A
22	Secondary AML (CMML)	70	40%	No	MF-0	46XY	Negative	Ara-C based induction chemotherapy	NE	N/A	N/A	N/A
23	CML-BC	64	60%	Yes- moderate splenomegaly on CT, not detected by physical exam	MF-0	46XX, t(9;22)	Negative	Hydroxyurea, Interferon, Imatinib, Nilotinib, Ara-C based chemotherapy, Dasatinib	NR	N/A	No	N/A

24	CML-BC	65	20%	Yes- splenomegaly on CT, 2.5 cm below costal margin on physical exam	MF-0	46XX, t(9;22)	Negative	Hydroxyurea	NR	No	No	N/A
25	Secondary AML (MPN)	66	20%	Yes- mild splenomegaly on CT, 4-5 cm below costal margin on physical exam	MF-0	46XY	Positive	Hydroxyurea	CR	Yes- spleen tip not palpable- cycle 1, day 30	N/A	MF-0
26	Secondary AML (CMML)	35	50%	No	MF-0	46XX, del(6)(p21p23)	Negative	Allogeneic SCT, Cyclophosphamide, Azacitidine	SD	N/A	No	MF-0
27	MPN (MF)	65	10%	Yes- marked splenomegaly on CT, crosses midline to below umbilicus on physical exam	MF-2	CK/MK	Negative	Hydroxyurea	NR	No	No	N/A
28	Secondary AML (CMML)	68	20%	No	MF-0	45X-Y	Negative	Entinostat, Azacitidine	SD	N/A	No	MF-0
29	Secondary AML (MPN)	66	46%	Yes- massive splenomegaly on CT, crosses midline to below umbilicus on physical exam	MF-3	47XX, +8	Negative	Flutamide/Prednison e, Azacitidine	NR	No	No	N/A
30	CMML	43	5%	No	MF-0	46XY	Negative	Hydroxyurea	NR	N/A	N/A	N/A
31	Secondary AML (MPN)	64	20%	Yes- splenomegaly on CT, 6-8 cm below costal margin on physical exam	MF-1	46XY	Positive	Hydroxyurea	CR	Yes- spleen tip not palpable- cycle 2, day 1	N/A	MF-0
32	MPN (PV)	73	10%	Yes- massive splenomegaly on CT, spleen crosses midline to below umbilicus on physical exam	MF-1	CK	Positive	Hydroxyurea	HI	No	No	MF-0
33	CMML	57	5%	Yes- splenomegaly on CT, not detected by physical exam	MF-1	46XY	Positive	Allogeneic SCT, Azacitidine	HI	N/A	N/A	MF-0
34	Secondary AML (MPN)	67	50%	No	MF-2	CK/MK	Positive	Splenectomy, Hydroxyurea	CR	N/A	Yes- partial clearance	MF-2
35	CMML	73	5%	No	MF-0	46XX	Negative	Splenectomy, Hydroxyurea	HI	N/A	N/A	MF-0
36	CMML	70	15%	No	MF-0	46XX	Negative	None	HI	N/A	N/A	MF-0
37	MPN (MF)	65	2%	Yes- marked splenomegaly on CT, spleen crosses	MF-3	46XY	Positive	Hydroxyurea, Lenalidomide/Prednison e	HI	Yes- spleen tip not palpable- cycle 2, day 21	N/A	MF-1

				midline to level of umbilicus, massively protuberant abdomen on physical exam								
--	--	--	--	---	--	--	--	--	--	--	--	--

- 1- CK = Complex karyotype
- 2- MK = Monosomal karyotype
- 3- NE = Non-evaluable
- 4- SD = Stable Disease